News US lawmakers take FDA to task over rare diseases record Lawmakers and patient advocates in the US are concerned that the FDA's regulation of rare disease therapies has been inconsistent and overly cautious.
News Generate's IPO gets over the line, raising $400m AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.
News Boehringer bets up to $500m on Sitryx immunology programme Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.
News Lilly says orforglipron tops Novo pill in diabetes trial Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.
News Asahi Kasei buys antiviral firm Aicuris for €780m Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.
News Changes at the top of Sarepta, Alkermes, as CEOs depart Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.